These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10443530)

  • 1. A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro.
    Moussazadeh M; Hua J; Sidhu MK; Zhao XX; Fitzgibbon JE; Liao MJ; Rashidbaigi A
    Antiviral Res; 1999 Jul; 42(3):177-87. PubMed ID: 10443530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
    Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
    J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
    Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
    Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
    Peng H; Callison D; Li P; Burrell C
    Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.
    Patick AK; Boritzki TJ; Bloom LA
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2159-64. PubMed ID: 9333041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance.
    Liem SE; Ramezani A; Li X; Joshi S
    Hum Gene Ther; 1993 Oct; 4(5):625-34. PubMed ID: 8280800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
    Connell EV; Hsu MC; Richman DD
    Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector.
    Venkatesh LK; Arens MQ; Subramanian T; Chinnadurai G
    Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8746-50. PubMed ID: 2247444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene.
    Ranga U; Woffendin C; Yang ZY; Xu L; Verma S; Littman DR; Nabel GJ
    J Virol; 1997 Sep; 71(9):7020-9. PubMed ID: 9261432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of primary human T cells from HIV infection by Trev: a transdominant fusion gene.
    Chinen J; Aguilar-Cordova E; Ng-Tang D; Lewis DE; Belmont JW
    Hum Gene Ther; 1997 May; 8(7):861-8. PubMed ID: 9143912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines.
    Ranki A; Lagerstedt A; Ovod V; Aavik E; Krohn KJ
    Arch Virol; 1994; 139(3-4):365-78. PubMed ID: 7832642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of a cell-based high-flux assay for the rev protein of HIV-1.
    Tang RY; Su Y
    J Virol Methods; 1997 May; 65(2):153-8. PubMed ID: 9186938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus type 1 protease inhibitors.
    McDonald CK; Kuritzkes DR
    Arch Intern Med; 1997 May; 157(9):951-9. PubMed ID: 9140265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression.
    Unwalla H; Banerjea AC
    Antiviral Res; 2001 Aug; 51(2):127-39. PubMed ID: 11431037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.